Journal article
Interplay of inflammatory markers and anti-SARS-CoV-2 antibodies in COVID-19 mortality: A prospective cohort study
International journal of infectious diseases, v 143, 107016
01 Jun 2024
PMID: 38521446
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
•Inflammatory levels during COVID-19 are linked to antibody concentrations.•Inflammation levels were significantly lower if antibody levels were >1200BAU/ml.•Combining inflammatory markers and antibodies improved mortality prediction.•Maintaining sufficient antibodies may protect vulnerable patients from poor outcomes.
Despite high global vaccination coverage, it remains unclear how vaccination and anti-SARS-CoV-2 antibodies affect immune responses and inflammation levels in patients with COVID-19. It is further unclear whether the inflammatory response differs depending on antibody levels and whether the combination of antibody and inflammation levels in COVID-19 patients affects mortality rates.
We conducted a prospective multicenter cohort study that included 1031 hospitalized COVID-19 patients from five hospitals. Anti-SARS-CoV-2-spike antibodies, interleukin-6 (IL6), and CRP were measured on hospital admission. The prespecified endpoint was all-cause in-hospital mortality.
We observed significantly lower levels of CRP (P<0.001) and IL6 (P<0.001) in patients with antibody levels above 1200 BAU/ml. After adjusting for potential confounders, patients with high levels of inflammatory markers (CRP>6 mg/dl or IL6>100 pg/ml) combined with low levels of anti-SARS-CoV-2-spike antibodies (<1200 BAU/ml) were approximately 8 times more likely to die than patients with low inflammatory responses and high antibody levels (CRP: aHR 7.973, 95% CI 2.744-23.169, P<0.001; IL6: aHR 8.973, 95% CI 3.549-22.688, P<0.001).
Hospitalized COVID-19 patients presenting with high inflammatory markers and low antibody levels exhibited the highest mortality risks. Higher antibody levels are associated with lower levels of inflammation in hospitalized COVID-19 patients.
Metrics
1 Record Views
Details
- Title
- Interplay of inflammatory markers and anti-SARS-CoV-2 antibodies in COVID-19 mortality: A prospective cohort study
- Creators
- Sylvia Mink - Private University in the Principality of LiechtensteinHeinz Drexel - Vorarlberg Institute for Vascular Investigation and TreatmentAndreas Leiherer - Landeskrankenhaus FeldkirchMatthias Frick - Landeskrankenhaus FeldkirchPatrick Reimann - Private University in the Principality of LiechtensteinChristoph H. Saely - Vorarlberg Institute for Vascular Investigation and TreatmentPeter Fraunberger - Private University in the Principality of Liechtenstein
- Publication Details
- International journal of infectious diseases, v 143, 107016
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001229171500001
- Scopus ID
- 2-s2.0-85190106505
- Other Identifier
- 991022202124404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- International collaboration
- Web of Science research areas
- Infectious Diseases